Bioneer is happy to announce that Kirsten Drejer, co-founder and former CEO of Symphogen has accepted to chair the Board of Directors at Bioneer from early spring 2017.

Kirsten is very well known to the Danish and international pharma and biotech community. Kirsten is M.Sc. in Pharmacy and holds a Ph.D in pharmacology. She had several scientific positions prior to entering a range of management roles at Novo Nordisk including Director of Diabetes Discovery and Corporate Facilitator.

Kirsten Drejer has been member of the Board at Danisco (now part of Dupont), The Danish Advanced Technology Fund and is currently member of the Board at Symphogen A/S and Vækstfonden. Since Kirsten stepped down from her role as founding CEO after 17 busy years she has also accepted board positions in BioPorto A/S and Lyhne & Co. In addition, Kirsten continues her engagement in promoting scientific development and entrepreneurship at the pharmaceutical department of University of Copenhagen and Copenhagen Business School.

Bioneer is very familiar to Kirsten who was a member of Bioneer’s Board from 2004 to 2011 but had to leave due to her duties at Symphogen.

New role as Chairman

When asked why she accepted a “come back” to Bioneer in a new role as Chairman of the Board Kirsten Drejer says:” It gives me great pleasure to be back at Bioneer and to be part of promoting advanced biotechnological services to Danish and foreign entrepreneurial companies; a good example of how cutting edge academic innovations can be turned into research-based services for companies in need of advanced analyses or manufacturing expertise.“

“I look forward to promoting the great work being done at Bioneer to relevant parties in my extensive network within the pharma and biotech arena“, Kirsten continues. “From my own experience as a biotech entrepreneur, I strongly believe that start-ups may increase their probability of surviving if they understand to use Intelligent Outsourcing to entities like Bioneer.

When confronted with the question on Bioneers role in the future. Kirsten adds, “My ambition is that Bioneer shall be a strong player in translational medical research by providing high-end services that will accelerate the transformation of new scientific insights to opportunities for Danish start-op companies – and to benefits for Danish patients. Through this role for Bioneer, I wish to support the highly commendable policy of the Danish Government to provide an innovation infrastructure in the form of the system of GTS institutes of which Bioneer is an example.”

Kirsten finally concludes, “I find that Bioneer, as a fully owned subsidiary of the Technical University of Denmark, is well positioned to facilitate that academic innovations at universities and hospitals can be used for the benefit of companies and, hence, to make sure that the investments in basic medical research and research facilities by the Danish society and Danish tax payers are converted, whenever possible, to significant opportunities for Danish companies and Danish patients.”

To get an overview of who else is currently on the board of Bioneer, follow the link.

Share this post